Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that ...

Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...

Despite a new supply commitment from Gilead Sciences, Doctors Without Borders/Médecins Sans Frontières (MSF) is poking holes ...

For Johanna Mercier, Gilead Sciences’ chief commercial and corporate affairs officer, leadership starts with a clear ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the 8 Best Quality Stocks to Buy According to Hedge Funds. Gilead Sciences Inc. ...

Gilead has tucked another drug candidate into a pipeline bulging from a recent deal flurry, paying $45 million to exercise ...

The AIDS Healthcare Foundation is criticizing Gilead Sciences over the cost of HIV medications. Advocates warn that high drug ...

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune ...

By Sriparna Roy April 7 (Reuters) - Gilead said on Tuesday it would acquire Germany-based Tubulis GmbH for up to $5 billion, ...

Gilead Sciences (GILD) stock is in focus as the company warns of a $107M Q1 earnings headwind from R&D deal charges as M&A ...

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and ...